Balancing Hormone Therapy: Mitigating Adverse Effects of Androgen-Deprivation Therapy and Exploring Alternatives in Prostate Cancer Management.
- Resource Type
- Academic Journal
- Authors
- Gudenkauf LM; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL.; Gray S; Salford Royal and The Christie NHS Foundation Trusts, Manchester, United Kingdom.; Genito-urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.; Gonzalez BD; Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL.; Sachdeva A; Genito-urinary Cancer Research Group, Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.; The Christie NHS Foundation Trust, Manchester, United Kingdom.; Autio K; Department of Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.
- Source
- Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101233985 Publication Model: Print Cited Medium: Internet ISSN: 1548-8756 (Electronic) Linking ISSN: 15488748 NLM ISO Abbreviation: Am Soc Clin Oncol Educ Book Subsets: MEDLINE
- Subject
- Language
- English
Androgen-deprivation therapy (ADT) is well established as the standard of care in metastatic prostate cancer (PCa) management; however, ADT has significant adverse effects (AEs) that must be addressed. This review aims to highlight opportunities to mitigate AEs of ADT and explore alternatives in PCa management. Specifically, we discuss behavioral and pharmacologic strategies for mitigating ADT AEs as well as ADT-sparing approaches for hormone-sensitive and castration-resistant PCa. Equipped with effective mitigation strategies and possible alternatives, clinicians and researchers can optimize health-related quality of life for patients currently receiving ADT for PCa and consider treatments that spare patients from AEs of ADT.